DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/dqqbz7/investigation) has announced the addition of the "Investigation Report on China Rituximab Market, 2009-2018" report to their offering.
Rituximab (trade names ""MabThera"" by Roche, ""Rituxan"" by Genetech) is a chimeric monoclonal antibody against the protein CD20 approved in 1997 to treat tumor. It is very effective and shows good tolerance in the treatment of B-cell lymphoma. As people understand more about B-cell and its action mechanism, it is acknowledged that besides B-cell malignancies rituximab can also treat autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and idiopathic thrombocytopenic purpura. Global sales revenue of rituximab is USD 5,034 million, USD 6,140 million and USD 7,143 million from 2010 to 2012 respectively.
Statistics shows that incidence of non-Hodgkin lymphomas in China has increased steeply from 20/1,000,000 at the end of the 20th century to 70/1,000,000 at present. Autoimmune diseases can harm central nervous system and organs such as lung, liver and kidney, leading to organ dysfunction and even organ failure. All of them can be life-threatening. Statistics shows that there are approximately 30 to 40 million people suffering from autoimmune diseases in China. Such high incidence should be taken seriously by the public.
Key Topics Covered:
1 Relevant Concepts of Rituximab
2 Market Overview of Rituximab in China, 2009-2013
3 Investigation on Sales Value of Rituximab in China, 2009-2013
4 Investigation on Market Share of Major Rituximab Manufacturers in China, 2009-2013
5 Investigation on Market Size of Rituximab by Dosage Form in China, 2009-2013
6 Reference Price of Rituximab in China Hospital Market, 2014
7 Major Manufacturers of Rituximab in China Market
8 Prospect of China Rituximab Market, 2014-2018
For more information visit http://www.researchandmarkets.com/research/dqqbz7/investigation
